Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.05
-0.20 (-1.10%)
Aug 3, 2026, 4:00 PM EDT - Market closed
Avalo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | 0.06 | 0.44 | 1.92 | 18.05 | 5.4 | |
Revenue Growth | - | -86.62% | -77.08% | -89.34% | 234.40% | -19.42% |
Cost of Revenue | - | - | -0.37 | 1.28 | 3.43 | 1.49 |
Gross Profit | - | 0.06 | 0.81 | 0.64 | 14.62 | 3.91 |
Selling, General & Admin | 24.21 | 22.9 | 17.24 | 10.3 | 20.71 | 24.66 |
Depreciation & Amortization Expenses | - | - | - | - | 0.04 | 1.55 |
Research & Development | 55.01 | 50.08 | 52.08 | 13.78 | 31.31 | 59.84 |
Other Operating Expenses | - | - | - | 3.91 | - | - |
Total Operating Expenses | 79.22 | 72.98 | 69.32 | 27.99 | 52.06 | 86.04 |
Operating Income | -79.16 | -72.93 | -68.51 | -27.35 | -37.44 | -82.13 |
Interest Income | 4.01 | 4.35 | 3.31 | -3.42 | - | - |
Interest Expense | - | - | - | - | -4.17 | -2.39 |
Other Non-Operating Income (Expense) | -9.43 | -9.52 | 30.19 | -0.76 | -0.02 | -0.02 |
Total Non-Operating Income (Expense) | -5.42 | -5.17 | 33.5 | -4.18 | -4.19 | -2.41 |
Pretax Income | -84.57 | -78.09 | -35.02 | -31.53 | -41.63 | -84.55 |
Provision for Income Taxes | 0.17 | 0.17 | 0.11 | 0.01 | 0.03 | -0.2 |
Net Income | -84.74 | -78.26 | -35.13 | -31.54 | -41.66 | -84.35 |
Earnings From Discontinued Operations | - | - | - | - | - | -0.03 |
Net Income to Common | -84.74 | -78.26 | -35.13 | -31.54 | -41.66 | -84.38 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 16 | 13 | 4 | 0 | 0 | - |
Shares Outstanding (Diluted) | 16 | 13 | 7 | 0 | 0 | - |
Shares Change | 60.67% | 78.82% | 2599.19% | 608.45% | - | - |
EPS (Basic) | -5.46 | -5.84 | -7.94 | -113.58 | -1063.00 | - |
EPS (Diluted) | -5.46 | -5.84 | -20.91 | -113.58 | -1063.00 | - |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -59.69 | -51.46 | -49.06 | -30.84 | -26.85 | -71.01 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -3.78 | -3.84 | -6.54 | -111.04 | -684.81 | - |
Gross Margin | - | 100.00% | 182.99% | 33.26% | 80.98% | 72.38% |
Operating Margin | - | -123602.00% | -15535.60% | -1421.57% | -207.41% | -1521.56% |
Profit Margin | - | -132642.00% | -7965.76% | -1639.50% | -230.78% | -1562.60% |
FCF Margin | - | -87216.90% | -11123.80% | -1602.81% | -148.72% | -1315.39% |
EBITDA | -78.93 | -72.58 | -68.34 | -27.19 | -37.27 | -80.48 |
EBITDA Margin | - | -123019.00% | -15497.30% | -1413.36% | -206.49% | -1490.87% |
EBIT | -79.16 | -72.93 | -68.51 | -27.35 | -37.44 | -82.13 |
EBIT Margin | - | -123602.00% | -15535.60% | -1421.57% | -207.41% | -1521.56% |
Effective Tax Rate | -0.20% | -0.21% | -0.33% | -0.04% | -0.07% | 0.23% |